Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)
Direct Payment
$105,000.00
Senescent fibroblasts modulate the immune response to pancreatic cancer
FY 2019-20
Summary
Pancreatic Ductal Adenocarcinoma (PDAC) is the most common pancreatic cancer (~93%) and the most lethal solid tumor type in Canada, with a 5 year survival rate of 8%. The Canadian Cancer Society estimated 5800 new cases and 5300 deaths due to pancreatic cancer in 2019. Furthermore, pancreatic cancer incidence continues to rise and is projected to become the second leading cause of cancer-related deaths in the United States by 2030. There remains no effective treatment or detection method for this devastating disease and new strategies are desperately needed. The refractory nature of PDAC has been attributed to its unique fibrotic tumor microenvironment (TME), which comprises 70-85% of tumor mass and is known to protect tumors from the effects of chemotherapy, radiotherapy, and immunotherapy. The PDAC TME is composed of a dense fibrotic matrix and an abundance of Cancer Associated Fibroblasts (CAFs) within a harsh environment. We believe that this harsh environment likely induces damage in the non-mutated CAFs and activates the stress response of senescence, which includes cell cycle arrest and the secretion of immune mediators. While senescent CAFs have been implicated in immunosuppression of skin cancer, their presence and role in PDAC remains unexplored. We have identified senescent CAFs in the PDAC TME of patient samples and mouse models. We hypothesize that these senescent CAFs contribute to immunosuppression and immunotherapy resistance in PDAC. To test this hypothesis, we will first assess the effects of senescent CAF depletion and co-implantation on the growth and biology of tumors in PDAC mouse models. Second, we will identify cellular, secreted, and transcriptional regulators of the senescent CAF phenotypes, to identify actionable molecular targets that can be targeted in PDAC combination immunotherapy strategies. Our work will provide novel insight into the PDAC TME and contribute to much needed progress in understanding and treating this lethal disease.
Department
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Recipient
Location
Missouri, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
415466
Name
Belle Jad
Region
Missouri
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Senescent fibroblasts modulate the immune response to pancreatic cancer
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Cancer Associated Fibroblast; Immunotherapy; Pancreatic Cancer; Senescence; Tumor Immunology; Tumor Microenvironment
Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is the most common pancreatic cancer (~93%) and the most lethal solid tumor type in Canada, with a 5 year survival rate of 8%. The Canadian Cancer Society estimated 5800 new cases and 5300 deaths due to pancreatic cancer in 2019. Furthermore, pancreatic cancer incidence continues to rise and is projected to become the second leading cause of cancer-related deaths in the United States by 2030. There remains no effective treatment or detection method for this devastating disease and new strategies are desperately needed. The refractory nature of PDAC has been attributed to its unique fibrotic tumor microenvironment (TME), which comprises 70-85% of tumor mass and is known to protect tumors from the effects of chemotherapy, radiotherapy, and immunotherapy. The PDAC TME is composed of a dense fibrotic matrix and an abundance of Cancer Associated Fibroblasts (CAFs) within a harsh environment. We believe that this harsh environment likely induces damage in the non-mutated CAFs and activates the stress response of senescence, which includes cell cycle arrest and the secretion of immune mediators. While senescent CAFs have been implicated in immunosuppression of skin cancer, their presence and role in PDAC remains unexplored. We have identified senescent CAFs in the PDAC TME of patient samples and mouse models. We hypothesize that these senescent CAFs contribute to immunosuppression and immunotherapy resistance in PDAC. To test this hypothesis, we will first assess the effects of senescent CAF depletion and co-implantation on the growth and biology of tumors in PDAC mouse models. Second, we will identify cellular, secreted, and transcriptional regulators of the senescent CAF phenotypes, to identify actionable molecular targets that can be targeted in PDAC combination immunotherapy strategies. Our work will provide novel insight into the PDAC TME and contribute to much needed progress in understanding and treating this lethal disease.
Competitiondate
201910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Belle, Jad
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~